PMID- 36385707
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20230415
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 129
IP  - 2
DP  - 2023 Jan 15
TI  - Combination of Deauville score and quantitative positron emission tomography 
      parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell 
      efficacy.
PG  - 255-263
LID - 10.1002/cncr.34532 [doi]
AB  - BACKGROUND: Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy 
      is an effective treatment for approximately 40% of relapsed/refractory large B 
      cell lymphomas (LBCL), and early identification of patients at risk for relapse 
      or progression after CAR T-cell therapy represents a clinical need. METHODS: The 
      authors conducted a single-center prospective study on 47 relapsed/refractory 
      LBCL receiving CAR T-cell therapy to evaluate the prognostic value of baseline 
      and after infusion (18) F-fluorodeoxyglucose positron emission tomography 
      (PET)-computed tomography. Qualitative and quantitative metabolic parameters were 
      evaluated before lymphodepletion, at day 30 and 90 post-infusion. RESULTS: Deep 
      variation of standardized uptake value (SUV)(mean) between baseline and day 30 
      correlated with response at day 90 (hazard ratio [HR], 1.49; 95% confidence 
      interval [CI], 1.01-2.2); p = .04) and better progression-free survival (PFS) 
      (HR, 0.63; 95% CI, 0.41-0.97); p = .04). In the overall population, 1-year PFS 
      was 63% for Deauville score (DS)1-3 and 39% for DS4-5 patients, respectively 
      (p = .02), however, the prognostic role of DS was lost when survivals are 
      analyzed by considering 38 patients not progressing at 30 days. In these 
      patients, in partial response or stable disease, the combination of DS and 
      variation of SUV(mean) allowed identification of three groups with different 
      prognosis: patients with DS1-3 and those with DS4-5 and decreased SUV(mean) had 
      similar 1-year PFS of 62% and 61%, whereas patients with DS4-5 and increased 
      SUV(mean) had a poorer 1-year PFS of 33% (p = .04). CONCLUSIONS: PET parameters 
      and association of DS and variation of SUV(mean) at 30 days could help in 
      identify patients at high risk of CAR T-cell failure. LAY SUMMARY: This is a 
      single-center prospective study on 47 lymphoma patients receiving commercial 
      chimeric antigen receptor T-cell therapy aimed to evaluate the prognostic value 
      of baseline and after infusion (18) F-fluorodeoxyglucose positron emission 
      tomography. Among patients in partial remission or stable disease at day 30, the 
      authors observed two subgroups with significantly different prognosis; patients 
      with Deauville score (DS)4-5 and a concomitant reduction of standardized uptake 
      value (SUV)(mean) had higher probability of long-lasting response than those with 
      DS4-5 and an increase of SUV(mean) .
CI  - (c) 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of 
      American Cancer Society.
FAU - Guidetti, Anna
AU  - Guidetti A
AUID- ORCID: 0000-0002-4195-6397
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
AD  - Department of Pathophysiology and Transplantation, University of Milano, Milano, 
      Italy.
FAU - Dodero, Anna
AU  - Dodero A
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Lorenzoni, Alice
AU  - Lorenzoni A
AD  - Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
FAU - Pizzamiglio, Sara
AU  - Pizzamiglio S
AD  - Department of Applied Research and Technological Development, Unit of 
      Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milano, Italy.
FAU - Argiroffi, Giovanni
AU  - Argiroffi G
AUID- ORCID: 0000-0002-0928-2927
AD  - Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
FAU - Chiappella, Annalisa
AU  - Chiappella A
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Bagnoli, Filippo
AU  - Bagnoli F
AUID- ORCID: 0000-0003-2371-6952
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Marasco, Vincenzo
AU  - Marasco V
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Carniti, Cristiana
AU  - Carniti C
AUID- ORCID: 0000-0003-1039-1757
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Monfrini, Chiara
AU  - Monfrini C
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Seregni, Ettore
AU  - Seregni E
AD  - Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
FAU - Pennisi, Martina
AU  - Pennisi M
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Verderio, Paolo
AU  - Verderio P
AD  - Department of Applied Research and Technological Development, Unit of 
      Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milano, Italy.
FAU - Alessi, Alessandra
AU  - Alessi A
AD  - Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
FAU - Corradini, Paolo
AU  - Corradini P
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
AD  - Department of Pathophysiology and Transplantation, University of Milano, Milano, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20221117
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Humans
MH  - *Receptors, Chimeric Antigen
MH  - Prospective Studies
MH  - Neoplasm Recurrence, Local
MH  - Positron-Emission Tomography/methods
MH  - Positron Emission Tomography Computed Tomography
MH  - Prognosis
MH  - *Lymphoma, B-Cell
MH  - Fluorodeoxyglucose F18
MH  - T-Lymphocytes
MH  - Retrospective Studies
MH  - *Lymphoma, Large B-Cell, Diffuse/diagnostic imaging/therapy
PMC - PMC10099560
OTO - NOTNLM
OT  - CAR T-cell
OT  - Deauville score
OT  - PET
OT  - SUV
OT  - lymphoma
COIS- Giovanni Argiroffi reports consulting fees from Fondazione IRCCS Istituto 
      Nazionale Tumori. Filippo Bagnoli reports consulting fees from Fondazione IRCCS 
      Ca' Granda Ospedale Maggiore Policlinico. Annalisa Chiappella reports consulting 
      fees from AstraZeneca, Celgene, Clinigen, Gilead Sciences, Incyte, Janssen 
      Biotech, Novartis, Roche, Secura Bio, and Takeda Oncology. Paolo Corradini 
      reports consulting fees from Gilead Sciences and Novartis. Anna Guidetti reports 
      consulting fees from Gilead Sciences and GlaxoSmithKline and travel fees from F. 
      Hoffmann-La Roche, Janssen Biotech, and Novartis. Martina Pennisi reports 
      consulting fees from Bristol-Myers Squibb, Gilead Sciences, and Nektar 
      Therapeutics and travel fees from Roche s.p.a. The other authors made no 
      disclosures.
EDAT- 2022/11/18 06:00
MHDA- 2022/12/24 06:00
PMCR- 2023/04/13
CRDT- 2022/11/17 11:30
PHST- 2022/09/14 00:00 [revised]
PHST- 2022/06/09 00:00 [received]
PHST- 2022/09/27 00:00 [accepted]
PHST- 2022/11/18 06:00 [pubmed]
PHST- 2022/12/24 06:00 [medline]
PHST- 2022/11/17 11:30 [entrez]
PHST- 2023/04/13 00:00 [pmc-release]
AID - CNCR34532 [pii]
AID - 10.1002/cncr.34532 [doi]
PST - ppublish
SO  - Cancer. 2023 Jan 15;129(2):255-263. doi: 10.1002/cncr.34532. Epub 2022 Nov 17.